Table 1. Disease and lymphoma... | American Society of Hematology

Table 1.

Disease and lymphoma development in SL3-3—infected BALB/c mice

Genotype	Virus	Disease incidence, % (no./total)	Lymphoma incidence,^*% (no./total)	Mean latency, d ± std†
WT	SL3-3	80 (8/10)	70 (7/10)	88 ± 32
Nfatc2^+/- c3^+/-	SL3-3	83 (40/48)	65 (31/48)	93 ± 45
Nfatc2^+/+ c3^-/-	SL3-3	100 (6/6)	100 (6/6)	80 ± 8
Nfatc2^+/- c3^-/-	SL3-3	100 (10/10)	80 (8/10)	83 ± 23
Nfatc2^-/- c3^+/+	SL3-3	93 (38/41)	63 (26/41)	108 ± 51
Nfatc2^-/- c3^+/-	SL3-3	89 (42/47)	60 (28/47)	110 ± 43
Pooled genotypes
WT	SL3-3	83 (48/58)	66 (38/58)	92 ± 44
WT	Mock	19 (4/21)	10 (2/21)	112 ± 60
Nfatc3^-/-	SL3-3	100 (16/16)	88 (14/16)	81 ± 21
Nfatc3^-/-	Mock	10 (1/10)	0 (0/10)	45‡
Nfatc2^-/-	SL3-3	91 (80/88)	60 (53/88)	109 ± 47
Nfatc2^-/-	Mock	61 (11/18)	17 (3/18)	116 ± 63

Genotype	Virus	Disease incidence, % (no./total)	Lymphoma incidence,^*% (no./total)	Mean latency, d ± std†
WT	SL3-3	80 (8/10)	70 (7/10)	88 ± 32
Nfatc2^+/- c3^+/-	SL3-3	83 (40/48)	65 (31/48)	93 ± 45
Nfatc2^+/+ c3^-/-	SL3-3	100 (6/6)	100 (6/6)	80 ± 8
Nfatc2^+/- c3^-/-	SL3-3	100 (10/10)	80 (8/10)	83 ± 23
Nfatc2^-/- c3^+/+	SL3-3	93 (38/41)	63 (26/41)	108 ± 51
Nfatc2^-/- c3^+/-	SL3-3	89 (42/47)	60 (28/47)	110 ± 43
Pooled genotypes
WT	SL3-3	83 (48/58)	66 (38/58)	92 ± 44
WT	Mock	19 (4/21)	10 (2/21)	112 ± 60
Nfatc3^-/-	SL3-3	100 (16/16)	88 (14/16)	81 ± 21
Nfatc3^-/-	Mock	10 (1/10)	0 (0/10)	45‡
Nfatc2^-/-	SL3-3	91 (80/88)	60 (53/88)	109 ± 47
Nfatc2^-/-	Mock	61 (11/18)	17 (3/18)	116 ± 63

Std indicates standard deviation.

Based on clear enlargement of lymphoid organs as described in “Materials and methods”

Mean latency is calculated for disease-developing mice

Only one mouse in the group developed disease; number indicates its lifespan